Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A11753" target="_blank" >RIV/00216208:11110/12:11753 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/12:11753

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.clineuro.2012.02.014" target="_blank" >http://dx.doi.org/10.1016/j.clineuro.2012.02.014</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

Popis výsledku v původním jazyce

Objective: To evaluate long-term effects of 2-year treatment with interferon beta combined with low-dose azathioprine and prednisone in multiple sclerosis. Methods: In the original 2-year ASA study, 181 patients with early relapsing-remitting multiple sclerosis were randomised into 3 treatment arms: those treated with interferon beta (n = 60), with interferon beta and low-dose azathioprine (n =58), and interferon beta, azathioprine and low-dose prednisone (n = 63). Of these, 172 were included in this 4-year non-study extension. Three monthly clinical controls and annual MRI scans were carried out. The primary endpoint was annual relapse activity. The secondary endpoints were disability and quantitative MRI parameters. Results: Nine patients were lost to follow-up and 172 were included in the analyses. None of relapse activity, disability accumulation or MRI parameters differed significantly between the groups over 6 years. Only 5.5% and 0.6% of patients were free from disease activity

Název v anglickém jazyce

Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort

Popis výsledku anglicky

Objective: To evaluate long-term effects of 2-year treatment with interferon beta combined with low-dose azathioprine and prednisone in multiple sclerosis. Methods: In the original 2-year ASA study, 181 patients with early relapsing-remitting multiple sclerosis were randomised into 3 treatment arms: those treated with interferon beta (n = 60), with interferon beta and low-dose azathioprine (n =58), and interferon beta, azathioprine and low-dose prednisone (n = 63). Of these, 172 were included in this 4-year non-study extension. Three monthly clinical controls and annual MRI scans were carried out. The primary endpoint was annual relapse activity. The secondary endpoints were disability and quantitative MRI parameters. Results: Nine patients were lost to follow-up and 172 were included in the analyses. None of relapse activity, disability accumulation or MRI parameters differed significantly between the groups over 6 years. Only 5.5% and 0.6% of patients were free from disease activity

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Neurology and Neurosurgery

ISSN

0303-8467

e-ISSN

—

Svazek periodika

114

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

7

Strana od-do

940-946

Kód UT WoS článku

000307855800020

EID výsledku v databázi Scopus

—